Botulinum Toxin for the Treatment of Neuropathic Pain

JungHyun Park, Hue Jung Park, JungHyun Park, Hue Jung Park

Abstract

Botulinum toxin (BoNT) has been used as a treatment for excessive muscle stiffness, spasticity, and dystonia. BoNT for approximately 40 years, and has recently been used to treat various types of neuropathic pain. The mechanism by which BoNT acts on neuropathic pain involves inhibiting the release of inflammatory mediators and peripheral neurotransmitters from sensory nerves. Recent journals have demonstrated that BoNT is effective for neuropathic pain, such as postherpetic neuralgia, trigeminal neuralgia, and peripheral neuralgia. The purpose of this review is to summarize the experimental and clinical evidence of the mechanism by which BoNT acts on various types of neuropathic pain and describe why BoNT can be applied as treatment. The PubMed database was searched from 1988 to May 2017. Recent studies have demonstrated that BoNT injections are effective treatments for post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia, and intractable neuropathic pain, such as poststroke pain and spinal cord injury.

Keywords: botulinum toxin; neuropathic pain; neuropathic pain treatment.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
(A) Noxious stimuli cause inflammation through the release of neuropeptides and inflammatory mediators, which can cause peripheral sensitization. This action also occurs in DRG, dorsal horn of spinal cord and can lead to central sensitization. Botulinum toxin (BoNT) inhibits the release of pain mediators in peripheral nerve terminal, DRG, and spinal cord neuron, thereby reducing the inflammatory response and preventing the development of peripheral and central sensitization. Symbols; SP, substance P; CGRP, calcitonin gene related protein; DRG, dorsal root ganglion; (B) The hyperexcitability and spontaneous action potential mediated by the Na channel in peripheral sensory neuron contribute to the pathophysiology of neuropathic pain. BoNT can control neuropathic pain by blocking the Na channel; (C) Some of the BoNT appear to retrograde transport along the axons. SNAP-25 is cleaved in the dorsal horn of the spinal cord and central nuclei after a small amount of BoNT is administered to the periphery, thereby boosting the retrograde transport of BoNT.

References

    1. Thenganatt M.A., Fahn S. Botulinum toxin for the treatment of movement disorders. Curr. Neurol. Neurosci. Rep. 2012;12:399–409. doi: 10.1007/s11910-012-0286-3.
    1. Pellizzari R., Rossetto O., Schiavo G., Montecucco C. Tetanus and botulinum neurotoxins: Mechanism of action and therapeutic uses. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1999;354:259–268. doi: 10.1098/rstb.1999.0377.
    1. Porta M. A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain. 2000;85:101–105. doi: 10.1016/S0304-3959(99)00264-X.
    1. Foster L., Clapp L., Erickson M., Jabbari B. Botulinum toxin A and chronic low back pain. A randomized, double-blind study. Neurology. 2001;56:1290–1293. doi: 10.1212/WNL.56.10.1290.
    1. Fishman L.M., Anderson C., Rosner B. BOTOX and physical therapy in the treatment of piriformis syndrome. Am. J. Phys. Med. Rehabil. 2002;81:936–942. doi: 10.1097/00002060-200212000-00009.
    1. Park H.J., Lee Y., Lee J., Park C., Moon D.E. The effects of botulinum toxin A on mechanical and cold allodynia in a rat model of neuropathic pain. Can. J. Anaesth. 2006;53:470–477. doi: 10.1007/BF03022619.
    1. Johnson E.A., Montecucco C. BOTULISM. In: Andrew G.E., editor. Handbook of Clinical Neurology. Elsevier; Amsterdam, The Netherlands: 2008. pp. 333–368.
    1. Montecucco C., Schiavo G. Mechanism of action of tetanus and botulinum neurotoxins. Mol. Microbiol. 1994;13:1–8. doi: 10.1111/j.1365-2958.1994.tb00396.x.
    1. Pantano S., Montecucco C. The blockade of the neurotransmitter release apparatus by botulinum neurotoxins. Cell. Mol. Life Sci. 2014;71:793–811. doi: 10.1007/s00018-013-1380-7.
    1. Whitemarsh R.C., Tepp W.H., Johnson E.A., Pellett S. Persistence of botulinum neurotoxin a subtypes 1–5 in primary rat spinal cord cells. PLoS ONE. 2014;9:e90252. doi: 10.1371/journal.pone.0090252.
    1. Park H.J., Marino M.J., Rondon E.S., Xu Q., Yaksh T.L. The effects of intraplantar and intrathecal botulinum toxin type B on tactile allodynia in mono and polyneuropathy in the mouse. Anesth. Analg. 2015;121:229–238. doi: 10.1213/ANE.0000000000000777.
    1. Choi E., Cho C.W., Kim H.Y., Lee P.B., Nahm F.S. Lumbar sympathetic block with botulinum toxin type B for complex regional pain syndrome: A case study. Pain Phys. 2015;18:911–916.
    1. Kharatmal S.B., Singh J.N., Sharma S.S. Voltage-gated sodium channels as therapeutic targets for treatment of painful diabetic neuropathy. Mini Rev. Med. Chem. 2015;15:1134–1147. doi: 10.2174/1389557515666150722112621.
    1. Meng J., Wang J., Lawrence G., Dolly J.O. Synaptobrevin I mediates exocytosis of cgrp from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J. Cell Sci. 2007;120:2864–2874. doi: 10.1242/jcs.012211.
    1. Durham P.L., Cady R. Insights into the mechanism of onabotulinumtoxinA in chronic migraine. Headache. 2011;51:1573–1577. doi: 10.1111/j.1526-4610.2011.02022.x.
    1. Fan C., Chu X., Wang L., Shi H., Li T. Botulinum toxin type A reduces TRPV1 expression in the dorsal root ganglion in rats with adjuvant-arthritis pain. Toxicon. 2017;133:116–122. doi: 10.1016/j.toxicon.2017.05.001.
    1. Lucioni A., Bales G.T., Lotan T.L., McGehee D.S., Cook S.P., Rapp D.E. Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammation. BJU Int. 2008;101:366–370. doi: 10.1111/j.1464-410X.2007.07312.x.
    1. Heikkila H.M., Hielm-Bjorkman A.K., Morelius M., Larsen S., Honkavaara J., Innes J.F., Laitinen-Vapaavuori O.M. Intra-articular botulinum toxin A for the treatment of osteoarthritic joint pain in dogs: A randomized, double-blinded, placebo-controlled clinical trial. Vet. J. 2014;200:162–169. doi: 10.1016/j.tvjl.2014.01.020.
    1. Hadley H.S., Wheeler J.L., Petersen S.W. Effects of intra-articular botulinum toxin type A (Botox®) in dogs with chronic osteoarthritis. Vet. Comp. Orthop. Traumatol. 2010;23:254–258. doi: 10.3415/VCOT-09-07-0076.
    1. Bach-Rojecky L., Dominis M., Lackovic Z. Lack of anti-inflammatory effects of botulinum toxin A in experimental models of inflammation. Fundam. Clin. Pharmacol. 2008;22:503–509. doi: 10.1111/j.1472-8206.2008.00615.x.
    1. Sycha T., Samal D., Chizh B., Lehr S., Gustorff B., Schnider P., Auff E. A lack of antinociceptive or antiinflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth. Analg. 2006;102:509–516. doi: 10.1213/01.ane.0000194447.46763.73.
    1. Chuang Y.C., Yoshimura N., Huang C.C., Wu M., Chiang P.H., Chancellor M.B. Intraprostatic botulinum toxin A injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat. J. Urol. 2008;180:742–748. doi: 10.1016/j.juro.2007.07.120.
    1. Cui M., Khanijou S., Rubino J., Aoki K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125–133. doi: 10.1016/j.pain.2003.10.008.
    1. Shin M.C., Wakita M., Xie D.J. Inhibition of membrane Na+ channels by A type botulinum toxin at femtomolar concentrations in central and peripheral neurons. J. Pharmacol. Sci. 2012;118:33–42. doi: 10.1254/jphs.11060FP.
    1. Matak I., Riederer P., Lacković Z. Botulinum toxin’s axonal transport from periphery to the spinal cord. Neurochem. Int. 2012;61:236–239. doi: 10.1016/j.neuint.2012.05.001.
    1. Bach-Rojecky L., Lackovic Z. Central origin of the antinociceptive action of botulinum toxin type A. Parmacol. Biochem. Behav. 2009;94:234–238. doi: 10.1016/j.pbb.2009.08.012.
    1. Bach-Rojecky L., Salkovic-Petrisic M., Lackovic Z. Botulinum toxin type A reduces pain supersensitivity in experimental diabetic neuropathy: Bilateral effects after unilateral injection. Eur. J. Pharmacol. 2010;633:10–14. doi: 10.1016/j.ejphar.2010.01.020.
    1. Favre-Guilmard C., Auguet M., Chabrier P.E. Different antinociceptive effects of botulinum toxin type A in inflammatory and peripheral polyneuropathic rat models. Eur. J. Pharmacol. 2009;617:48–53. doi: 10.1016/j.ejphar.2009.06.047.
    1. Tang-Liu D.D., Aoki K.R., Dolly J.O., de Paiva A., Houchen T.L., Chasseaud L.F., Webber C. Intramuscular injection of 125I-botulinum neurotoxin-complex versus 125I-botulinum-free neurotoxin: Time course of tissue distribution. Toxicon. 2003;42:461–469. doi: 10.1016/S0041-0101(03)00196-X.
    1. Marinelli S., Vacca V., Ricordy R., Uggenti C., Tata A.M., Luvisetto S., Pavone F. The analgesic effect on neuropathic pain of retrogradely transported botulinumneurotoxin A involves Schwann cells and astrocytes. PLoS ONE. 2012;7:e47977. doi: 10.1371/journal.pone.0047977.
    1. Wu C.J., Lian Y.J., Zheng Y.K., Zhang H.F., Chen Y., Xie N.C., Wang L.J. Botulinum toxin type A for the treatment of trigeminal neuralgias: Results from a randomized, double-blind, placebo-controlled trial. Cephalgia. 2012;32:443–450. doi: 10.1177/0333102412441721.
    1. Zhang H., Lian Y., Ma Y., Chen Y., He C., Xie N., Wu C. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: Observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J. Headache Pain. 2014;15:65. doi: 10.1186/1129-2377-15-65.
    1. Zuniga C., Piedimonte F., Diaz S., Micheli F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin. Neuropharmacol. 2013;36:146–150. doi: 10.1097/WNF.0b013e31829cb60e.
    1. Bohluli B., Motamedi M.H., Bagheri S.C., Bayat M., Lassemi E., Navi F., Moharamnejad N. Use of botulinum toxin A for drug-refractory trigeminal neuralgia: Preliminary report. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2011;111:47–50. doi: 10.1016/j.tripleo.2010.04.043.
    1. Zuniga C., Diaz S., Piedimonte F., Micheli F. Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq. Neuropsiquiatr. 2008;66:500–503. doi: 10.1590/S0004-282X2008000400012.
    1. Turk U., Ilhan S., Alp R., Sur H. Botulinum toxin and intractable trigeminal neuralgia. Clin. Neuropharmacol. 2005;28:161–162.
    1. Xiao L., Mackey S., Hui H., Xong D., Zhang Q., Zhang D. Subcutaneous injection of botulinum toxin A is beneficial in postherpetic neuralgia. Pain Med. 2010;11:1827–1833. doi: 10.1111/j.1526-4637.2010.01003.x.
    1. Apalla Z., Sotiriou E., Lallas A., Lazaridou E., Ioannides D. Botulinum toxin A in postherpetic neuralgia: A parallel, randomized, double-blind, single-dose, placebo-controlled trial. Clin. J. Pain. 2013;29:857–864. doi: 10.1097/AJP.0b013e31827a72d2.
    1. Liu H.T., Tsai S.K., Kao M.C., Hu J.S. Botulinum toxin A relieved neuropathic pain in a case of post-herpetic neuralgia. Pain Med. 2006;7:89–91. doi: 10.1111/j.1526-4637.2006.00100.x.
    1. Sotiriu E., Apalla Z., Panagiotidou D., Ioannidis D. Severe post-herpetic neuralgia successfully treated with botulinum toxin A: Three case reports. Acta Derm.-Venereol. 2009;89:214–215.
    1. Ranoux D., Attal N., Morain F., Bouhassira D. Botulinum toxin type A induces direct analgesic effects in chronic neuropathic pain. Ann. Neurol. 2008;64:274–283. doi: 10.1002/ana.21427.
    1. Layeeque R., Hochberg J., Siegel E., Kunkel K., Kepple J., Henry-Tillman R.S., Dunlap M., Seibert J., Klimberg V.S. Botulinum toxin infiltration for pain control after mastectomy and expander reconstruction. Ann. Surg. 2004;240:608–613. doi: 10.1097/01.sla.0000141156.56314.1f.
    1. Fabregat G., Asensio-Samper J.M., Palmisani S., Villanueva-Pérez V.L., De Andrés J. Subcutaneous botulinum toxin for chronic post-thoracotomy pain. Pain Pract. 2013;13:231–234. doi: 10.1111/j.1533-2500.2012.00569.x.
    1. Rostami R., Mittal S.O., Radmand R., Jabbari B. Incobotulinum toxin-A improves post-surgical and post-radiation pain in cancer patients. Toxins. 2016;8:22. doi: 10.3390/toxins8010022.
    1. Yuan R.Y., Sheu J.J., Yu J.M., Chen W.T., Tseng I.J., Change H.H., Hu C.J. Botulinum toxin for diabetic neuropathic pain: A randomized double-blind crossover trial. Neurology. 2009;72:1473–1478. doi: 10.1212/.
    1. Ghasemi M., Ansari M., Basiri K., Shaigannejad V. The effects of intradermal botulinum toxin type A injections on pain symptoms of patients with diabetic neuropathy. J. Res. Med. Sci. 2014;19:106–111.
    1. Lakhan S.E., Velasco D.N., Tepper D. Botulinum toxin-A for painful diabetic neuropathy: A meta-analysis. Pain Med. 2015;16:1773–1780. doi: 10.1111/pme.12728.
    1. Kapural L., Stillman M., Kapural M., Mclntyre P., Guirgius M., Mekhail N. Botulinum toxin occipital nerve block for the treatment of severe occipital neuralgia: A case series. Pain Pract. 2007;7:337–340. doi: 10.1111/j.1533-2500.2007.00150.x.
    1. Taylor M., Silva S., Cottrell C. Botulinum toxin type A in the treatment of occipital neuralgia: A pilot study. Headache. 2008;48:1476–1481. doi: 10.1111/j.1526-4610.2008.01089.x.
    1. Breuer B., Sperber K., Wallenstein S., Kiprovski K., Calapa A., Snow B., Pappagallo M. Clinically significant placebo analgesic response in a pilot trial of botulinum B in patients with hand pain and carpel tunnel syndrome. Pain Med. 2006;7:16–24. doi: 10.1111/j.1526-4637.2006.00084.x.
    1. Tsai C.P., Liu C.Y., Lin K.P., Wnag K.C. Efficacy of botulinum toxin type A in the relief of carpal tunnel syndrome. Clin. Drug Investig. 2006;26:511–515. doi: 10.2165/00044011-200626090-00004.
    1. Safarpour D., Jabbari B. Botulinum toxin a (Botox) for treatment of proximal myofascial pain in complex regional pain syndrome: Two cases. Pain Med. 2010;11:1415–1418. doi: 10.1111/j.1526-4637.2010.00929.x.
    1. Safarpour D., Salardini A., Richardson D., Jabbari B. Botulinum toxin A for treatment of allodynia of complex regional pain syndrome: A pilot study. Pain Med. 2010;11:1411–1414. doi: 10.1111/j.1526-4637.2010.00897.x.
    1. Carroll I., Clark J.D., Mackey S. Sympathetic block with botulinum toxin to treat complex regional pain syndrome. Ann. Neurol. 2009;65:348–351. doi: 10.1002/ana.21601.
    1. Argoff C.E. Botulinum toxin type A treatment of myofascial pain in patients with CRPS Type 1 (reflex sympathetic dystrophy): A pilot study; Proceedings of the World Pain Congress (IASP) Meeting; Vienna, Austria. 22–27 August 1999.
    1. Kharkar S., Ambady P., Venkatesh Y., Schwartzman R.J. Intramuscular botulinum toxin in complex regional pain syndrome: Case series and literature review. Pain Phys. 2011;14:419–424.
    1. Wu H., Sultana R., Taylor K.B., Szabo A. A prospective randomized double-blinded pilot study to examine the effect of botulinum toxin type A injection vs. Lidocaine/Depomedrol injection on residual and phantom limb pain. Clin. J. Pain. 2012;28:108–112. doi: 10.1097/AJP.0b013e3182264fe9.
    1. Kern U., Martin C., Scheicher S., Muler H. Long-term treatment of phantom and stump pain with Botulinum toxin type A over 12 months. A first clinical observation. Nervenarzt. 2004;75:336–340. doi: 10.1007/s00115-003-1657-4.
    1. Han Z.A., Song D.H., Oh H.M., Chung M.E. Botulinum toxin type A for neuropathic pain in patients with spinal cord injury. Ann. Neurol. 2016;79:569–578. doi: 10.1002/ana.24605.
    1. Li G., Lv C.A., Tian L., Jin L.J., Sun P., Zhao W. A randomized controlled trial of botulinum toxin A for treating neuropathic pain in patients with spinal cord injury. Medicine. 2017;96:e6919. doi: 10.1097/MD.0000000000006919.
    1. Jabbari B., Maher N., Difazio M.P. Botulinum toxin A improved burning pain and allodynia in two patients with spinal cord pathology. Pain Med. 2003;4:206–210. doi: 10.1046/j.1526-4637.2003.03013.x.
    1. Han Z.A., Song D.H., Chung M.E. Effect of subcutaneous injection of botulinum toxin A on spinal cord injury-associated neuropathic pain. Spinal Cord. 2014;52:S5–S6. doi: 10.1038/sc.2014.43.
    1. Shippen C., Bavikatte G., Mackarel D. The benefit of botulinum toxin A in the management of central post stroke pain: A case report. J. Neurol. Stroke. 2017;6:00218. doi: 10.15406/jnsk.2017.06.00218.
    1. Camoes-Barbosa A., Neves A.F. The analgesic effect of abobotulinum and incobotulinum toxins type A in central poststroke pain: Two case reports. PM&R. 2016;8:384–387.
    1. Wissel J., Ganapathy V., Ward A.B., Borg J., Ertzgaard P., Herrmann C., Haggstrom A., Sakel M., Ma J., Dimitrova R., et al. Onabotulinum toxin A improves pain in patients with post-stroke spasticity: Findings from a randomized, double-blind, placebo-controlled trial. J. Pain Symptom Manag. 2016;52:17–26. doi: 10.1016/j.jpainsymman.2016.01.007.
    1. Sławek J., Madaliński M.H., Maciag-Tymecka I., Duzyński W. Frequency of side effects after botulinum toxin A injections in neurology, rehabilitation and gastroenterology. Pol. Merkur. Lek. 2005;18:298–302.
    1. Kessler K.R., Skutta M., Benecke R. Longterm treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency. German Dystonia Study Group. J. Neurol. 1999;246:265–274. doi: 10.1007/s004150050345.
    1. Greene P., Fahn S., Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov. Disord. 1994;9:213–217. doi: 10.1002/mds.870090216.
    1. Moon Y.E., Choi J.H., Park H.J., Park J.H., Kim J.H. Ultrasound-guided nerve block with botulinum toxin type A for intractable neuropathic pain. Toxins. 2016;8 doi: 10.3390/toxins8010018.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe